Dana-Farber Cancer Institute
44 Binney Street
About Dana-Farber Cancer InstituteThe mission of Dana-Farber Cancer Institute is to provide expert, compassionate care to children and adults with cancer while advancing the understanding, diagnosis, treatment, cure, and prevention of cancer and related diseases. As an affiliate of Harvard Medical School and a Comprehensive Cancer Center designated by the National Cancer Institute, the Institute also provides training for new generations of physicians and scientists, designs programs that promote public health particularly among high-risk and underserved populations, and disseminates innovative patient therapies and scientific discoveries to our target community across the United States and throughout the world.
Dana-Farber Cancer Institute's ultimate goal is the eradication of cancer, AIDS, and related diseases and the fear that they engender.
Above all else, we make a difference by relieving the burden of disease now and for the future through our research, clinical care, education, outreach and advocacy.
We pursue excellence relentlessly and with integrity in all that we do, adhering always to the highest standards of conduct.
Compassion and Respect
For those in our care and for one another.
We foster the spirit of inquiry, promoting collaboration and innovation across traditional boundaries while celebrating individual creativity.
273 articles with Dana-Farber Cancer Institute
Resolution Liquid Biopsy Assay Outperforms Guardant360 in Retrospective Non-Small Cell Lung Carcinoma Comparison Pilot Study
Scientists from Dana-Farber Cancer Institute present results demonstrating detection of more actionable oncogenic fusions today at AACR Annual Meeting
Cancer Research UK, a cancer research and awareness charity in the United Kingdom and Isle of Man, recently announced its latest Grand Challenge winners. This cancer research grant awards a series of £20 million wards to international, multidisciplinary teams that focus on unique and new approach...
The American Society of Hematology is holding its 60th Annual Meeting & Exposition starting December 1 and running through December 4 in San Diego. Most of the players, big and small, in cancer drug therapies will be there, presenting updates and breaking stories about their hematology pipelines.
The Center for Protein Degradation will build upon the work of Dana-Farber researchers Nathanael Gray, PhD and Eric Fischer, PhD
Joseph Eid, head of medical at BMS, said Empliciti in combination with pomalidomide and dexamethasone has provided proof that the medication can extend the time a patient can live without the worsening of his or her disease.
Kazia Enters Clinical Collaboration to Investigate Use of Brain Cancer Drug GDC-0084 in Breast Cancer
Kazia Therapeutics announced today that it will collaborate with world-leading treatment and research centre Dana-Farber Cancer Institute to investigate the use of Kazia's potential new therapy for brain cancer, GDC-0084, in breast cancer that has spread to the brain.
Each Chocolate Bar Purchased in the Dana-Farber Holiday Cards & Gifts Collection Helps Support Pediatric and Adult Cancer Care and Research
10/15/2018Who mixed things up in the biotech world this past week? Pfizer announces its leadership team, Rheos gets a new COO, and board of directors updates from multiple biopharma companies.
9/24/2018Here's a look at who's making moves in the biotech and pharma world this week.
Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced the formation of a Scientific Advisory Board (SAB), consisting of several world-renowned immuno-oncology and drug development professionals.
8/3/2018There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
Extension of research collaboration focused on enhancing and speeding the process of bringing new and advanced treatments to cancer patients
NurOwn® is the company's ongoing randomized, double-blind, multi-dose Phase 3 clinical trial in patients with amyotrophic lateral sclerosis
Lustgarten-Funded Research Impacting Patients in Real Time
Royal Philips announced it will be implementing Clinical Pathways from the Dana-Farber Cancer Institute
Foghorn Therapeutics has officially launched with a $50 million investment and the ambitious goal of altering the way our genes work.
Guardant Health Release: New Research Reveals Molecular Heterogeneity of Metastatic Gastroesophageal Cancer
The study suggests that patients with these cancers could benefit from targeted therapy based on the detection of biomarkers found with a comprehensive liquid biopsy, but that were absent from their primary tumor.
With this gift, the PMC has brought its fundraising total to$598M since its inception in 1980.
The Parker Institute for Cancer Immunotherapy today announced that researchers at Dana-Farber Cancer Institute have joined its network.
Dana-Farber Cancer Institute Release: PCF-Funded ICECaP Study Identifies Earlier Clinical Trial Endpoint That Can Be Used To Indicate Effectiveness Of New Treatments